Skip to main content

Select Drug Profiles

FDA Approvals, In the News

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

In Silico Pharmacology

David B. Nash, MD, MBA

Original Research

The Prevalence and Determinants of Controlled Substance Discrepancies in a Level I Trauma Hospital

Chukwuma Anyanwu, PharmD, MPH, MBA, Oliver Egwim, PharmD, MBA

Stakeholder Perspective

Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders

by Jack E. Fincham, PhD, RPh

Original Research

Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation

Qing Lee, PhD, Michelle Mocarski, MPH, Shawn X. Sun, PhD

Stakeholder Perspective

Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden

by Gary Branning, MBA

Practice Management

Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain

Ancilla W. Fernandes, PhD, David M. Kern, PhD, Catherine Datto, MD, MS, Yen-Wen Chen, PhD, Charles McLeskey, MD, Ozgur Tunceli, PhD

Stakeholder Perspective

Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?

by Gary M. Owens, MD

Conference Highlights AMCP

Implications of Real-World Data and Pharmacoeconomics for Managed Care

Lilly Ostrovsky

Practice Management

Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?

Stanton R. Mehr

In the News, Lung Cancer, Oncology

New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation

Lilly Ostrovsky

Lilly Ostrovsky

Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer

Lilly Ostrovsky

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas

Page 111 of 244
Results 1101 - 1110 of 2438